Marsh McLennan (MRSH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Mar, 2026Voting matters and shareholder proposals
Election of 13 directors is up for vote at the annual meeting scheduled for May 21, 2026, with the board recommending a vote for each nominee.
Advisory (nonbinding) vote on named executive officer compensation is included, with board support.
Ratification of the selection of the independent registered public accounting firm is on the agenda, recommended by the board.
Board of directors and corporate governance
The slate of director nominees includes Anthony K. Anderson, Bruce Broussard, John Q. Doyle, H. Edward Hanway, Peter Harrison, Judith Hartmann, Deborah C. Hopkins, Tamara Ingram, Jane H. Lute, Steven A. Mills, Morton O. Schapiro, Jan Siegmund, and Lloyd M. Yates.
Executive compensation and say-on-pay
Shareholders are asked to cast a nonbinding advisory vote to approve the compensation of named executive officers.
Latest events from Marsh McLennan
- Strong 2025 results, robust governance, and high say-on-pay support highlight this proxy filing.MRSH
Proxy filing31 Mar 2026 - 2025 revenue up 10%, adjusted EPS up 9%, and $2.0B in share repurchases.MRSH
Q4 202527 Feb 2026 - Q2 revenue up 6%, EPS up 10%, margin 29%, and dividend raised 15% amid robust growth.MRSH
Q2 20243 Feb 2026 - Q3 revenue up 6%, strong segment growth, and $7.75B McGriff acquisition announced.MRSH
Q3 202419 Jan 2026 - Strong 2024 growth, record acquisitions, and margin expansion set up a positive 2025 outlook.MRSH
Q4 20249 Jan 2026 - Q1 2025 revenue up 9%, adjusted EPS up 5%, with strong segment growth and capital returns.MRSH
Q1 202519 Dec 2025 - Strong 2024 results, robust governance, and key votes on directors, pay, auditor, and equity plan.MRSH
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, pay, auditor, and incentive plan, all board-backed.MRSH
Proxy Filing1 Dec 2025 - Q2 2025 delivered 12% revenue growth, 11% EPS gain, and a 10% dividend increase.MRSH
Q2 20255 Nov 2025